Latest News

Heading 1

with a request body that specifies how to map the columns of your import file to the associated CRM properties in HubSpot.... In the request JSON, define the import file details, including mapping the spreadsheet's columns to HubSpot data. Your request JSON should include the following fields:... entry for each column.

Heading 1

Filter

News (5)

10 Highlighted Research Accomplishments from 2023

January 10, 2024

2023 marks yet another record-breaking year in our pursuit of treatments for Prader-Willi (PWS) and Schaaf-Yang (SYS) syndromes. In this blog, we shine a spotlight on 10 research accomplishments from 2023, each contributing to a deeper understanding of PWS and

Improving the PWS Clinical Trial Experience for Families and Clinical Study Site Staff

November 29, 2023

It has been an exciting time for PWS research and clinical trials. The field has been working hard to find effective treatments for the symptoms of PWS to help our children lead more independent and fulfilling lives. In the last

fpwr-partners-with-pwsa-usa-to-introduce-the-boss-social-skills-curriculum-for-teens-and-adults-with-pws

FPWR Partners with PWSA | USA to Provide BOSS Social Skills Groups for Teens and Adults with PWS

September 27, 2023

PWSA | USA (Prader-Willi Syndrome Association | USA) and FPWR (Foundation for Prader-Willi Research) are thrilled to announce a groundbreaking collaboration to address the social challenges faced by individuals with Prader-Willi syndrome (PWS). FPWR funding has facilitated the development of

Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

September 26, 2023

We are excited to share the news that Soleno has announced positive, statistically significant top-line results from the randomized withdrawal period of study c602 of DCCR for Prader-Willi Syndrome. In the study, patients taking DCCR showed a highly significant improvement

Aardvark Announces Rare Disease Designation and Expands Ongoing Phase 2 Trial

August 3, 2023

Aardvark Therapeutics, a clinical stage biopharmaceutical company, has reported receipt of a Rare Pediatric Disease Designation in Prader-Willi Syndrome (PWS) from the FDA for its lead program ARD-101. This designation means Aardvark is eligible for a Rare Pediatric Disease Priority

Innovative FPWR-Funded Projects Receive Additional Funding

May 23, 2023

FPWR’s grant program focuses on supporting innovative, high risk/high reward research in its early stages, with particular emphasis on supporting projects that will lead to new treatments for PWS. One important objective of the grant program is to provide funding

New Venture Philanthropy Investment: Palobiofarma

May 4, 2023

The Foundation for Prader-Willi Research (FPWR) has provided a new venture philanthropy award, in the form of a convertible loan, to Palobiofarma S.L., a Spanish biopharmaceutical company focused on developing innovative treatments for serious diseases. Palobiofarma has a robust pipeline

FPWR Announces 2022 Champion of Hope Award Winner

September 28, 2022

The Foundation for Prader-Willi Research (FPWR) is thrilled to announce the recipient of the 2022 Champion of Hope Award, James Resnick, PhD. The Champion of Hope Award was established to recognize individuals who have made impactful contributions toward FPWR’s mission

FDA Committee Indicates Substantial Evidence Has Not Been Provided For the Effectiveness of Carbetocin as a Treatment for PWS

November 4, 2021

In a disappointing decision, a panel of independent advisers to the Food and Drug Administration has voted 12 to 1 suggesting that Levo Therapeutics has not provided substantial evidence of effectiveness for carbetocin nasal spray (LV-101) in the treatment of

Previous 3 4 5 6 7

Older Articles

Subscribe to hope.

If you're looking for the latest information on Prader-Willi syndrome, you’ve come to the right place. FPWR Updates is your source for up-to-date information.

Subscribe to FPWR News Updates

Heading 1